文献速递淋巴瘤

复发/难治套细胞淋巴瘤中疾病进展时间与二线BTK抑制剂治疗结局

Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma.
PubMed 文献 · Blood Adv · 2023-01-01

本研究在8个国际中心纳入360例一线含利妥昔单抗治疗后首次启用二线布鲁顿酪氨酸激酶抑制剂(BTKi)的复发/难治套细胞淋巴瘤患者,评估疾病进展时间(POD)与临床/病理因素对无进展生存(PFS2)和总生存(OS2)的预测价值,并构建列线图与预后指数。POD时间、Ki67≥30%和MCL国际预后指数(MIPI)与PFS2和OS2相关,两队列C指数均≥0.68。

要点

  • POD时间、Ki67≥30%和MIPI与二线BTKi治疗的PFS2和OS2相关。
  • 二线BTKi MIPI区分高危(2年PFS2 14%)、中危(50%)、低危(64%)三组。
  • 基于列线图和预后指数的网络/应用计算器可估算PFS2和OS2。

核心结论

  • POD时间、Ki67和MIPI与接受二线BTKi的复发/难治套细胞淋巴瘤患者的生存结局相关。
  • 纳入这些变量的简单临床模型可能有助于规划替代疗法,如嵌合抗原受体T细胞疗法、异基因干细胞移植或具有替代作用机制的新药。

研究设计与样本

  • 多中心研究,纳入8个国际中心(7个主队列,1个验证队列)的患者。
  • 共纳入360例患者,主队列160例,验证队列200例。
  • 构建多变量模型评估POD时间与临床/病理因素的关联,并转化为列线图和预后指数。
  • 患者均为一線含利妥昔单抗治疗后首次启用二线BTKi的复发/难治套细胞淋巴瘤患者。

主要发现

  • POD时间、Ki67≥30%和MIPI与从二线BTKi开始计算的无进展生存(PFS2)和总生存(OS2)相关。
  • 两个队列的C指数均≥0.68。
  • 二线BTKi MIPI识别出3组2年PFS2不同的患者:高危组14%,中危组50%,低危组64%。
  • 构建了基于列线图和预后指数的网络/应用计算器以估算PFS2和OS2。

关键数值与推荐

  • Ki67≥30%为纳入多变量模型的阈值。
  • 二线BTKi MIPI将患者分为高危、中危、低危3组,2年PFS2分别为14%、50%、64%。

临床怎么用

  • 作者认为,纳入POD时间、Ki67和MIPI的简单临床模型可能有助于规划替代疗法,如嵌合抗原受体T细胞疗法、异基因干细胞移植或具有替代作用机制的新药。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Time to progression of disease (POD) after first-line (1L) therapy is prognostic in mantle cell lymphoma (MCL), although studies have included a broad range of 1L, second-line (2L), and subsequent lines of therapy. The purpose of this study was to evaluate the factors predicting outcomes in patients with relapsed/refractory (R/R) MCL exclusively initiating 2L Bruton's tyrosine kinase inhibitors (BTKis) after 1L rituximab-containing therapy. Patients were accrued from 8 international centers (7 main, 1 validation cohort). Multivariable models evaluating the association between time to POD and clinical/pathologic factors were constructed and converted into nomograms and prognostic indexes predicting outcomes in this population. A total of 360 patients were included, including 160 in the main cohort and 200 in the validation cohort. Time to POD, Ki67 ≥ 30%, and MCL International Prognostic Index (MIPI) were associated with progression-free survival (PFS2) and overall survival (OS2) from the start of 2L BTKis. C-indexes were consistently ≥0.68 in both cohorts. Web/application-based calculators based on nomograms and prognostic indexes to estimate PFS2 and OS2 were constructed. The 2L BTKi MIPI identifies 3 groups with distinct 2-year PFS2, including high risk (14%), intermediate risk (50%), and low risk (64%). Time to POD, Ki67, and MIPI are associated with survival outcomes in patients with R/R MCL receiving 2L BTKis. Simple clinical models incorporating these variables may assist in planning for alternative therapies such as chimeric antigen receptor T-cell therapy, allogeneic stem cell transplantation, or novel agents with alternative mechanisms of action.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Villa D, Jiang A, Visco C, et al. Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma. Blood Adv. 2023. PMID: 37307169. doi:10.1182/bloodadvances.2023009804

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。